Syncor to Sell or Close Home-Infusion Facilities
- Share via
Syncor International Corp. said it plans to shed its home-infusion unit, which accounts for about 6% of its business.
Syncor’s total revenue in its fiscal year ended May 31, 1992, was $210.2 million. The company primarily provides radiopharmaceuticals and other specialty drugs, such as those for diagnostic imaging, to hospitals and clinics.
The Chatsworth-based company plans to close four of its home-infusion sites--which provide intravenous-therapy products for patients at home--and to sell the remaining nine facilities.
Syncor also announced that for the past 15 months, it has been developing plans for a national pharmacy system to deliver therapies to oncologists, or cancer specialists. Pilot tests of the system will continue into Syncor’s 1994 fiscal year.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
